Navigation Links
ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
Date:12/6/2011

h the Securities and Exchange Commission for the periods ended March 31, 2011, June 30, 2001 and September 30, 2011, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release are made as of the date hereof and may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. These forward looking statements should not be relied upon as representing our assessments as of any date subsequent to the date of this press release.

Halozyme Safe Harbor Statement

 In addition to historical information, the statements set forth above regarding the subcutaneous Cinryze with rHuPH20 product candidate, its possible advantages and attributes,  the anticipated presentation of the complete data from the initial Phase 2 trial referenced in this press release, future clinical trials plans, including the anticipated Phase 2 dose ranging efficacy combination trial, and other statements regarding Halozyme's product candidates and potential attributes of these product candidates, involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning.  Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including clinical trial results, delays in development, possible adverse events associated with the use of the product candidate, regulatory delays and competitive conditions. These and other factors that may result in differences are discussed in greater de
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ViroPharma to Participate in Two November Healthcare Investor Conferences
2. ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline
3. ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
4. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
5. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
6. ViroPharma Announces Additional Securities Repurchase Program
7. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
8. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
9. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
10. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
11. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research and ... Hypodermic Needles Market 2014-2018" report to their offering. ... A hypodermic needle is a hollow needle commonly used ... or or to extract fluids from it. A hypodermic ... to inject substances that cannot be ingested. Hypodermic needles ...
(Date:7/11/2014)... New York , July 11, 2014 ... by Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic ... Size, Share, Growth, Trends and Forecast, 2013-2019" the global ... in 2012 and is expected to grow at a ... an estimated value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... -- Neurelis, Inc. ("Neurelis") today announced an agreement with ... by Biotie to purchase Neurelis, clearing the way for ... for pediatric and adult epilepsy patients who experience acute ... has advanced the development program for NRL-1 and worked ... required for NDA submission to the FDA.  Given the ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
(Date:7/14/2014)... Summer is the best season of the year for ... and other outdoor adventures. The promotional product experts at ... all summer long. The promo product gurus at 4AllPromos have ... imprinted products everyone must have on hand this summer. ... Sunscreen helps protect skin from harmful UV rays produced ...
(Date:7/14/2014)... Crystal Dental has recently announced that it ... been made via LAD Solutions in in order to increase ... made in order to draw in new patients that can ... Crystal Dental offers a variety of services for both routine ... Dental include cosmetic dentistry procedures such as porcelain veneers and ...
(Date:7/13/2014)... 14, 2014 FORT LEE, N.J. – Authors ... modern approach to the science of tooth implants ... This book describes recent advances and techniques in the ... that benefit people who have lost all of their natural ... the first lower subperiosteal implant in 1940. It was ...
(Date:7/13/2014)... Recently, TopDresses100.com, a popular dress company in ... multi-colored Quinceanera dresses to its product line. ... colorful outfits are guaranteed to be quality made. Now, ... off. , TopDresses100.com has a wide variety of elegant ... items are in stock and ready to ship. As ...
(Date:7/13/2014)... July 13, 2014 Manchester United and ... the 2014 Guinness International Champions Cup. The 2014 ICC ... each year because of the talent of it brings in. ... AS Roma will compete in the 2014 event spread across ... 24 with a game between Olympiacos and Milan and will ...
Breaking Medicine News(10 mins):Health News:Why These Three Summer Essentials from 4AllPromos Can Improve Summer 2Health News:Crystal Dental Announces the Opening of New Office Location in Sacramento 2Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 2Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 3Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 4Health News:Cheap Multi-colored Quinceanera Dresses From TopDresses100.com 2Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 2Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 3
... Established under the DOD Congressionally Directed Medical Research ... WASHINGTON, July 23 Today, Lung Cancer Alliance (LCA) announced ... is allotting approximately $1.2 million of the $20 million lung cancer ... , , (Logo: ...
... , , , ... , , SAN DIEGO, July 23 ... medical device company focused on developing products for minimally disruptive surgical treatments for the ... , NuVasive reported second quarter revenue of $88.5 million, a ...
... , , WASHINGTON, July ... elected John W. Bluford, president and CEO of Truman Medical Centers ... assume the chairmanship in 2011, becoming the top elected official of ... , , Bluford has been ...
... WASHINGTON, July 23 The Food and Drug Institute (FDLI) ... updated biographical information on recent Obama Administration appointees, including FDA Commissioner ... , The FDA Directory ... FDA personnel available, and contains listings of more than two dozen ...
... the epidemic might be slowing down among poor families ... preschoolers from low-income families in the United States are considered ... report finds that the news is not all bad: The ... children in this group. , Among 2- to 4-year-olds from ...
... , Woman spent remaining life in wheelchair, nursing facilities ... type , , KENT, Wash., July 23 ... Renton woman more than $1.8 million yesterday for a medical center,s ... routine back surgery. , , The ...
Cached Medicine News:Health News:Lung Cancer Alliance Announces First 'Request For Bids' for Department of Defense Lung Cancer Research Program 'Concept Awards' 2Health News:NuVasive Reports Second Quarter 2009 Financial Results 2Health News:NuVasive Reports Second Quarter 2009 Financial Results 3Health News:NuVasive Reports Second Quarter 2009 Financial Results 4Health News:NuVasive Reports Second Quarter 2009 Financial Results 5Health News:NuVasive Reports Second Quarter 2009 Financial Results 6Health News:NuVasive Reports Second Quarter 2009 Financial Results 7Health News:NuVasive Reports Second Quarter 2009 Financial Results 8Health News:NuVasive Reports Second Quarter 2009 Financial Results 9Health News:NuVasive Reports Second Quarter 2009 Financial Results 10Health News:NuVasive Reports Second Quarter 2009 Financial Results 11Health News:NuVasive Reports Second Quarter 2009 Financial Results 12Health News:AHA Board Elects John Bluford Chair-Elect Designate 2Health News:AHA Board Elects John Bluford Chair-Elect Designate 3Health News:1 in 7 Low-Income Preschoolers Is Obese 2Health News:Jury Awards Valley Medical Center Patient $1.8 Million for Nursing Negligence 2Health News:Jury Awards Valley Medical Center Patient $1.8 Million for Nursing Negligence 3
... The table-mounted knee ... exposure for total knee ... flexible, open-frame design allows ... the knee during the ...
... NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2) is a ... predicting acute renal failure with a >90% ... especially in urine, as early as 2 ... an ideal diagnostic marker for acute renal ...
... an assayed quality control material used for ... hemoglobin fractions on CO-Oximeter instrumentation. It provides ... that parallels the human physiologic range for ... available in three (3) levels for monitoring ...
... is an assayed quality control ... measurements of total hemoglobin and ... It is available in three ... performance at varying points within ...
Medicine Products: